<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35449467</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1613-7671</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>9-10</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Wiener klinische Wochenschrift</Title><ISOAbbreviation>Wien Klin Wochenschr</ISOAbbreviation></Journal><ArticleTitle>Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>419</EndPage><MedlinePgn>399-419</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00508-022-02018-x</ELocationID><Abstract><AbstractText>The Austrian Society of Pneumology (ASP) launched a first statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in May 2020, at a time when in Austria 285 people had died from this disease and vaccinations were not available. Lockdown and social distancing were the only available measures to prevent more infections and the breakdown of the health system. Meanwhile, in Austria over 13,000 patients have died in association with a SARS-CoV&#x2011;2 infection and coronavirus disease 2019 (COVID-19) was among the most common causes of death; however, SARS-CoV&#x2011;2 has been mutating all the time and currently, most patients have been affected by the delta variant where the vaccination is very effective but the omicron variant is rapidly rising and becoming predominant. Particularly in children and young adults, where the vaccination rate is low, the omicron variant is expected to spread very fast. This poses a particular threat to unvaccinated people who are at elevated risk of severe COVID-19 disease but also to people with an active vaccination. There are few publications that comprehensively addressed the special issues with SARS-CoV&#x2011;2 infection in patients with chronic lung diseases. These were the reasons for this updated statement. Pulmonologists care for many patients with an elevated risk of death in case of COVID-19 but also for patients that might be at an elevated risk of vaccination reactions or vaccination failure. In addition, lung function tests, bronchoscopy, respiratory physiotherapy and training therapy may put both patients and health professionals at an increased risk of infection. The working circles of the ASP have provided statements concerning these risks and how to avoid risks for the patients.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olschewski</LastName><ForeName>Horst</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2834-7466</Identifier><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. horst.olschewski@medunigraz.at.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria. horst.olschewski@medunigraz.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eber</LastName><ForeName>Ernst</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Tirol Kliniken, Hospital Hochzirl-Natters, Natters, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hackner</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pneumology, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handzhiev</LastName><ForeName>Sabin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pneumology, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoetzenecker</LastName><ForeName>Konrad</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idzko</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Medicine&#xa0;II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klepetko</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamprecht</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Faculty of Medicine, Johannes-Kepler-University, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;ffler-Ragg</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pulmonology, Department of Internal Medicine&#xa0;II, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meilinger</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Pulmonology, Klinik Floridsdorf, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Klinik Floridsdorf, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prior</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Specialist for pulmonology, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Otmar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Internal and Respiratory Medicine, Hospital Graz&#xa0;II, Hospital Enzenbach, Gratwein, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xe4;ubl</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Tirol Kliniken, Hospital Hochzirl-Natters, Natters, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zacharasiewicz</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric and Adolescent Medicine, Klinik Ottakring, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwick</LastName><ForeName>Ralf Harun</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Outpatient Pulmonary Rehabilitation, Therme Wien Med, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arns</LastName><ForeName>Britt-Madelaine</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>First Medical Department, Hanusch Hospital, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolitschek</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Ordensklinikum Linz Elisabethinen Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cima</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Tirol Kliniken, Hospital Hochzirl-Natters, Natters, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gingrich</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Specialist for pulmonology, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochmair</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horak</LastName><ForeName>Fritz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Allergy Center Vienna West, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaksch</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kropfm&#xfc;ller</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Faculty of Medicine, Johannes-Kepler-University, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfleger</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puchner</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Reha Zentrum M&#xfc;nster, M&#xfc;nster, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puelacher</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Interdisciplinary sleep laboratory, Telfs, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salzer</LastName><ForeName>Helmut J F</ForeName><Initials>HJF</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Faculty of Medicine, Johannes-Kepler-University, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Landesklinikum Hochegg, Grimmenstein, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stelzm&#xfc;ller</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Specialist for pulmonology, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strenger</LastName><ForeName>Volker</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urban</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Pulmonology, Klinik Floridsdorf, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Marlies</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wimberger</LastName><ForeName>Franz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Ordensklinikum Linz Elisabethinen Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flick</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Wien Klin Wochenschr</MedlineTA><NlmUniqueID>21620870R</NlmUniqueID><ISSNLinking>0043-5325</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008171" MajorTopicYN="Y">Lung Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015272" MajorTopicYN="Y">Pulmonary Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic lung disease</Keyword><Keyword MajorTopicYN="N">Immune modulators</Keyword><Keyword MajorTopicYN="N">Long covid</Keyword><Keyword MajorTopicYN="N">Mechanical ventilation</Keyword><Keyword MajorTopicYN="N">Pediatric lung disease</Keyword></KeywordList><CoiStatement>H.&#xa0;Flick: advisory boards and presentations on COVID-19 for Boehringer-Ingelheim. H.&#xa0;Olschewski, E.&#xa0;Eber, B.&#xa0;Bucher, K.&#xa0;Hackner, S.&#xa0;Handzhiev, K.&#xa0;Hoetzenecker, M.&#xa0;Idzko, W.&#xa0;Klepetko, G.&#xa0;Kovacs, B.&#xa0;Lamprecht, J.&#xa0;L&#xf6;ffler-Ragg, M.&#xa0;Meilinger, A.&#xa0;M&#xfc;ller, C.&#xa0;Prior, O.&#xa0;Schindler, H.&#xa0;T&#xe4;ubl, A.&#xa0;Zacharasiewicz, R.H.&#xa0;Zwick, B.-M.&#xa0;Arns, J.&#xa0;Bolitschek, K.&#xa0;Cima, E.&#xa0;Gingrich, M.&#xa0;Hochmair, F.&#xa0;Horak, P.&#xa0;Jaksch, R.&#xa0;Kropfm&#xfc;ller, A.&#xa0;Pfleger, B.&#xa0;Puchner, C.&#xa0;Puelacher, P.&#xa0;Rodriguez, H.J.F.&#xa0;Salzer, P.&#xa0;Schenk, I.&#xa0;Stelzm&#xfc;ller, V.&#xa0;Strenger, M.&#xa0;Urban, M.&#xa0;Wagner and F.&#xa0;Wimberger declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35449467</ArticleId><ArticleId IdType="pmc">PMC9022736</ArticleId><ArticleId IdType="doi">10.1007/s00508-022-02018-x</ArticleId><ArticleId IdType="pii">10.1007/s00508-022-02018-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383(16):1522&#x2013;1534. doi: 10.1056/NEJMoa2020283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2020283</ArticleId><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Umnuaypornlert A, Kanchanasurakit S, Lucero-Prisno DEI, Saokaew S. Smoking and risk of negative outcomes among COVID-19 patients: a systematic review and meta-analysis. Tob Induc Dis. 2021;19:09. doi: 10.18332/tid/132411.</Citation><ArticleIdList><ArticleId IdType="doi">10.18332/tid/132411</ArticleId><ArticleId IdType="pmc">PMC7857247</ArticleId><ArticleId IdType="pubmed">33551713</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO R&amp;D blueprint novel Coronavirus, COVID-19, therapeutic trial synopsis. 2020. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf?ua=1. Accessed 10&#xa0;Jan 2022.</Citation></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5):e2111417. doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabady S, Altenberger J, Brose M, Denk-Linnert DM, Fertl E, Gotzinger F, et al. Guideline S1: Long COVID: Diagnostics and treatment strategies. Wien Klin Wochenschr. 2021;133(Suppl&#xa0;7):237&#x2013;278. doi: 10.1007/s00508-021-01974-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-021-01974-0</ArticleId><ArticleId IdType="pmc">PMC8633909</ArticleId><ArticleId IdType="pubmed">34851455</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian H, Miao T, Liu L, Zheng X, Luo D, Li Y. Indoor transmission of SARS-CoV-2. Indoor Air. 2021;31(3):639&#x2013;645. doi: 10.1111/ina.12766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ina.12766</ArticleId><ArticleId IdType="pubmed">33131151</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard M, Kok A, de Meulder D, Bestebroer TM, Lamers MM, Okba NMA, et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun. 2020;11(1):3496. doi: 10.1038/s41467-020-17367-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17367-2</ArticleId><ArticleId IdType="pmc">PMC7343828</ArticleId><ArticleId IdType="pubmed">32641684</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuch G. Breathing is enough: for the spread of influenza virus and SARS-CoV-2 by breathing only. J Aerosol Med Pulm Drug Deliv. 2020;33(4):230&#x2013;234. doi: 10.1089/jamp.2020.1616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jamp.2020.1616</ArticleId><ArticleId IdType="pmc">PMC7406993</ArticleId><ArticleId IdType="pubmed">32552296</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson J, Chartier Y, Pessoa-Silva CL, Jensen P, Li Y, Seto WH. Natural ventilation for infection control in health-care settings. WHO; 2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">23762969</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320&#x2013;329. doi: 10.1056/NEJMoa2107058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107058</ArticleId><ArticleId IdType="pmc">PMC8262622</ArticleId><ArticleId IdType="pubmed">34192428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng B, Yuan M, Ma Q, Wang S, Tan Y, Xu Y, et al. Landscape of SARS-CoV-2 spike protein-interacting cells in human tissues. Int Immunopharmacol. 2021;95:107567. doi: 10.1016/j.intimp.2021.107567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107567</ArticleId><ArticleId IdType="pmc">PMC7945790</ArticleId><ArticleId IdType="pubmed">33756225</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, Segerstolpe A, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021;595(7865):107&#x2013;113. doi: 10.1038/s41586-021-03570-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03570-8</ArticleId><ArticleId IdType="pmc">PMC8919505</ArticleId><ArticleId IdType="pubmed">33915569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch A, Dupont A, Goutay J, Caplan M, Staessens S, Moussa M, et al. Endotheliopathy is induced by plasma from critically ill patients and associated with organ failure in severe COVID-19. Circulation. 2020;142(19):1881&#x2013;1884. doi: 10.1161/CIRCULATIONAHA.120.050907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050907</ArticleId><ArticleId IdType="pmc">PMC7643783</ArticleId><ArticleId IdType="pubmed">32970476</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A, Vecchi&#xe9; A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021;21(5):319&#x2013;329. doi: 10.1038/s41577-021-00536-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00536-9</ArticleId><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnhuber&#xa0;A, Fliesser&#xa0;E, Gorkiewicz&#xa0;G, Zacharias&#xa0;M, Seeliger&#xa0;B, David&#xa0;S, et&#xa0;al. Between inflammation and thrombosis: endothelial cells in COVID-19. Eur Respir&#xa0;J. 2021;58(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112008</ArticleId><ArticleId IdType="pubmed">33958433</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D, Bridgewood C, Ramanan AV, Meaney JFM, Watad A. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol. 2021;3(3):e224&#x2013;e33. doi: 10.1016/S2665-9913(20)30420-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30420-3</ArticleId><ArticleId IdType="pmc">PMC7832717</ArticleId><ArticleId IdType="pubmed">33521655</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med. 2020;202(3):356&#x2013;360. doi: 10.1164/rccm.202006-2157CP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202006-2157CP</ArticleId><ArticleId IdType="pmc">PMC7397783</ArticleId><ArticleId IdType="pubmed">32539537</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaisher&#x2019;s DMJJ. 1862 account of balloon sickness: altitude, decompression injury, and hypoxemia. Neurology. 2003;60(6):1016&#x2013;1018. doi: 10.1212/01.WNL.0000048663.44594.A2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000048663.44594.A2</ArticleId><ArticleId IdType="pubmed">12654971</ArticleId></ArticleIdList></Reference><Reference><Citation>Flick H, Arns BM, Bolitschek J, Bucher B, Cima K, Gingrich E, et al. Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9&#xa0;May 2020): statement of the Austrian Society of Pneumology (ASP) Wien Klin Wochenschr. 2020;132(13/14):365&#x2013;386. doi: 10.1007/s00508-020-01691-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-020-01691-0</ArticleId><ArticleId IdType="pmc">PMC7291190</ArticleId><ArticleId IdType="pubmed">32533443</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators A, Investigators AC-a. Investigators R-C, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790&#x2013;802. doi: 10.1056/NEJMoa2105911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical. Trial. JAMA internal medicine. 2021;181(12):1612&#x2013;1620. doi: 10.1001/jamainternmed.2021.6203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6203</ArticleId><ArticleId IdType="pmc">PMC8498934</ArticleId><ArticleId IdType="pubmed">34617959</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators R-C, Investigators AC-a. Investigators A, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777&#x2013;789. doi: 10.1056/NEJMoa2103417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103417</ArticleId><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620&#x2013;1630. doi: 10.1001/jama.2021.4152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.4152</ArticleId><ArticleId IdType="pmc">PMC7974835</ArticleId><ArticleId IdType="pubmed">33734299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluge S, Janssens U, Welte T, Weber-Carstens S, Sch&#xe4;lte G, Spinner CD, et al. S3-Leitlinie &#x2013; Empfehlungen zur station&#xe4;ren Therapie von Patienten mit COVID-19. 2021. https://www.awmf.org/uploads/tx_szleitlinien/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19__2021-05.pdf. Accessed 10&#xa0;Jan 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">33450783</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH . ACTIV trial of blood thinners pauses enrollment of critically ill COVID-19 patients. 2020.</Citation></Reference><Reference><Citation>Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Eur Respir&#xa0;J. 2019 doi: 10.1183/13993003.01647-2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01647-2019</ArticleId><ArticleId IdType="pubmed">31473594</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a&#xa0;European Respiratory Society living guideline. Eur Respir J. 2021 doi: 10.1183/13993003.00048-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00048-2021</ArticleId><ArticleId IdType="pmc">PMC7947358</ArticleId><ArticleId IdType="pubmed">33692120</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickens CO, Gao CA, Cuttica MJ, Smith SB, Pesce LL, Grant RA, et al. Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia. Am J Respir Crit Care Med. 2021;204(8):921&#x2013;932. doi: 10.1164/rccm.202106-1354OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202106-1354OC</ArticleId><ArticleId IdType="pmc">PMC8534629</ArticleId><ArticleId IdType="pubmed">34409924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewig S, Kolditz M, Pletz M, Altiner A, Albrich W, Dromann D, et al. Management of adult community-acquired pneumonia and prevention&#x2014;update 2021. Pneumologie. 2021;75(9):665&#x2013;729. doi: 10.1055/a-1497-0693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1497-0693</ArticleId><ArticleId IdType="pubmed">34198346</ArticleId></ArticleIdList></Reference><Reference><Citation>Fekkar A, Lampros A, Mayaux J, Poignon C, Demeret S, Constantin JM, et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am J Respir Crit Care Med. 2021;203(3):307&#x2013;317. doi: 10.1164/rccm.202009-3400OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202009-3400OC</ArticleId><ArticleId IdType="pmc">PMC7874326</ArticleId><ArticleId IdType="pubmed">33480831</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalhoff K, Abele-Horn M, Andreas S, Deja M, Ewig S, Gastmeier P, et al. Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia&#x2014;update 2017. Pneumologie. 2018;72(1):15&#x2013;63. doi: 10.1055/s-0043-121734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0043-121734</ArticleId><ArticleId IdType="pubmed">29341032</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149&#x2013;e62. doi: 10.1016/S1473-3099(20)30847-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30847-1</ArticleId><ArticleId IdType="pmc">PMC7833078</ArticleId><ArticleId IdType="pubmed">33333012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a&#xa0;retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY CG Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a&#xa0;randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637&#x2013;1645. doi: 10.1016/S0140-6736(21)00676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a&#xa0;retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325&#x2013;e331. doi: 10.1016/S2665-9913(20)30127-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30127-2</ArticleId><ArticleId IdType="pmc">PMC7252085</ArticleId><ArticleId IdType="pubmed">32501454</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimaraes PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406&#x2013;415. doi: 10.1056/NEJMoa2101643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101643</ArticleId><ArticleId IdType="pmc">PMC8220898</ArticleId><ArticleId IdType="pubmed">34133856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795&#x2013;807. doi: 10.1056/NEJMoa2031994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407&#x2013;1418. doi: 10.1016/S2213-2600(21)00331-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00331-3</ArticleId><ArticleId IdType="pmc">PMC8409066</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81(2):318&#x2013;356. doi: 10.1016/j.jinf.2020.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7177073</ArticleId><ArticleId IdType="pubmed">32333918</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020;81(4):647&#x2013;679. doi: 10.1016/j.jinf.2020.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.052</ArticleId><ArticleId IdType="pmc">PMC7313480</ArticleId><ArticleId IdType="pubmed">32592703</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20&#x2013;30. doi: 10.1056/NEJMoa2030340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2030340</ArticleId><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas IO, Br&#xe4;u N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503&#x2013;1516. doi: 10.1056/NEJMoa2028700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028700</ArticleId><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al. Effect of anakinra on mortality in patients with COVID-19: a&#xa0;systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3(10):e690&#x2013;e7. doi: 10.1016/S2665-9913(21)00216-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00216-2</ArticleId><ArticleId IdType="pmc">PMC8352496</ArticleId><ArticleId IdType="pubmed">34396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a&#xa0;double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752&#x2013;1760. doi: 10.1038/s41591-021-01499-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01499-z</ArticleId><ArticleId IdType="pmc">PMC8516650</ArticleId><ArticleId IdType="pubmed">34480127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Author correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a&#xa0;double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1850. doi: 10.1038/s41591-021-01569-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01569-2</ArticleId><ArticleId IdType="pmc">PMC8500253</ArticleId><ArticleId IdType="pubmed">34625750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed antiviral drugs for Covid-19&#x2014;interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497&#x2013;511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19&#x2014;final report. N Engl J Med. 2020;383(19):1813&#x2013;1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305&#x2013;315. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos RV, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509&#x2013;520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384(10):905&#x2013;914. doi: 10.1056/NEJMoa2033130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033130</ArticleId><ArticleId IdType="pmc">PMC7781100</ArticleId><ArticleId IdType="pubmed">33356051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-coV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229&#x2013;237. doi: 10.1056/NEJMoa2029849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2029849</ArticleId><ArticleId IdType="pmc">PMC7646625</ArticleId><ArticleId IdType="pubmed">33113295</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385(13):1184&#x2013;1195. doi: 10.1056/NEJMoa2109682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109682</ArticleId><ArticleId IdType="pmc">PMC8362593</ArticleId><ArticleId IdType="pubmed">34347950</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a&#xa0;neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238&#x2013;251. doi: 10.1056/NEJMoa2035002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035002</ArticleId><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460&#x2013;470. doi: 10.1001/jama.2020.10044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10044</ArticleId><ArticleId IdType="pmc">PMC7270883</ArticleId><ArticleId IdType="pubmed">32492084</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) BMJ. 2020;371:m3939. doi: 10.1136/bmj.m3939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3939</ArticleId><ArticleId IdType="pmc">PMC7578662</ArticleId><ArticleId IdType="pubmed">33093056</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, V&#xe1;zquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619&#x2013;629. doi: 10.1056/NEJMoa2031304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031304</ArticleId><ArticleId IdType="pmc">PMC7722692</ArticleId><ArticleId IdType="pubmed">33232588</ArticleId></ArticleIdList></Reference><Reference><Citation>Group RC. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a&#xa0;randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605&#x2013;612. doi: 10.1016/S0140-6736(21)00149-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00149-5</ArticleId><ArticleId IdType="pmc">PMC7884931</ArticleId><ArticleId IdType="pubmed">33545096</ArticleId></ArticleIdList></Reference><Reference><Citation>Furtado RHM, Berwanger O, Fonseca HA, Corr&#xea;a TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a&#xa0;randomised clinical trial. Lancet. 2020;396(10256):959&#x2013;967. doi: 10.1016/S0140-6736(20)31862-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31862-6</ArticleId><ArticleId IdType="pmc">PMC7836431</ArticleId><ArticleId IdType="pubmed">32896292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalcanti AB, Berwanger O, Zampieri FG. Hydroxychloroquine with or without azithromycin in Covid-19. Reply. N Engl J Med. 2021;384(2):191.</Citation><ArticleIdList><ArticleId IdType="pubmed">33264542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. Int J Antimicrob Agents. 2020;56(4):106143. doi: 10.1016/j.ijantimicag.2020.106143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106143</ArticleId><ArticleId IdType="pmc">PMC7445147</ArticleId><ArticleId IdType="pubmed">32853672</ArticleId></ArticleIdList></Reference><Reference><Citation>Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial. EClinicalMedicine. 2021;37:100959. doi: 10.1016/j.eclinm.2021.100959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100959</ArticleId><ArticleId IdType="pmc">PMC8225706</ArticleId><ArticleId IdType="pubmed">34189446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021;32:100720. doi: 10.1016/j.eclinm.2020.100720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100720</ArticleId><ArticleId IdType="pmc">PMC7816625</ArticleId><ArticleId IdType="pubmed">33495752</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikirti RR, Pattadar C, Raj R, Agarwal N, Biswas B, et al. Evaluation of ivermectin as a&#xa0;potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in eastern India. J Pharm Pharm Sci. 2021;24:343&#x2013;350. doi: 10.18433/jpps32105.</Citation><ArticleIdList><ArticleId IdType="doi">10.18433/jpps32105</ArticleId><ArticleId IdType="pubmed">34265236</ArticleId></ArticleIdList></Reference><Reference><Citation>Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcal&#xe1; D&#xed;az JF, L&#xf3;pez Miranda J, Bouillon R, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203:105751. doi: 10.1016/j.jsbmb.2020.105751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2020.105751</ArticleId><ArticleId IdType="pmc">PMC7456194</ArticleId><ArticleId IdType="pubmed">32871238</ArticleId></ArticleIdList></Reference><Reference><Citation>Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a&#xa0;single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. 2021;325(11):1053&#x2013;1060. doi: 10.1001/jama.2020.26848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.26848</ArticleId><ArticleId IdType="pmc">PMC7890452</ArticleId><ArticleId IdType="pubmed">33595634</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695&#x2013;1704. doi: 10.1016/S0140-6736(20)31042-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31042-4</ArticleId><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041&#x2013;2052. doi: 10.1056/NEJMoa2019014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2019014</ArticleId><ArticleId IdType="pmc">PMC7397242</ArticleId><ArticleId IdType="pubmed">32706953</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-coV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.8857</ArticleId><ArticleId IdType="pubmed">32330277</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269&#x2013;271. doi: 10.1038/s41422-020-0282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030&#x2013;2040. doi: 10.1056/NEJMoa2022926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022926</ArticleId><ArticleId IdType="pmc">PMC7556338</ArticleId><ArticleId IdType="pubmed">33031652</ArticleId></ArticleIdList></Reference><Reference><Citation>Windisch W, Weber-Carstens S, Kluge S, Rossaint R, Welte T, Karagiannidis C. Invasive and non-invasive ventilation in patients with COVID-19. Dtsch Arztebl Int. 2020;117(31/32):528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658682</ArticleId><ArticleId IdType="pubmed">32900426</ArticleId></ArticleIdList></Reference><Reference><Citation>Windisch W, Schonhofer B, Majorski DS, Wollsching-Strobel M, Criee CP, Schwarz SB, et al. Role of non-invasive strategies in the treatment of acute hypoxemic respiratory failure related to COVID-19. Pneumologie. 2021;75(6):424&#x2013;431. doi: 10.1055/a-1486-1015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1486-1015</ArticleId><ArticleId IdType="pubmed">33975371</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021&#xa0;patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):853&#x2013;862. doi: 10.1016/S2213-2600(20)30316-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30316-7</ArticleId><ArticleId IdType="pmc">PMC7386882</ArticleId><ArticleId IdType="pubmed">32735842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumoli N, Florian C, Cei M, Evangelista I, Colombo A, Razionale G, et al. Palliative care in a&#xa0;COVID-19 internal medicine ward: a preliminary report. Int J Infect Dis. 2021;105:141&#x2013;143. doi: 10.1016/j.ijid.2021.02.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.02.053</ArticleId><ArticleId IdType="pmc">PMC7885636</ArticleId><ArticleId IdType="pubmed">33607302</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaro RP, MacLaren G, Brodie D. ECMO support for COVID-19: a&#xa0;balancing act&#x2014;Authors&#x2019; reply. Lancet. 2021;397(10269):95. doi: 10.1016/S0140-6736(20)32517-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32517-4</ArticleId><ArticleId IdType="pmc">PMC7832424</ArticleId><ArticleId IdType="pubmed">33422256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cypel M, Keshavjee S. When to consider lung transplantation for COVID-19. Lancet Respir Med. 2020;8(10):944&#x2013;946. doi: 10.1016/S2213-2600(20)30393-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30393-3</ArticleId><ArticleId IdType="pmc">PMC7447224</ArticleId><ArticleId IdType="pubmed">32857989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang C, Jaksch P, Hoda MA, Lang G, Staudinger T, Tschernko E, et al. Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a&#xa0;PCR-positive patient. Lancet Respir Med. 2020;8(10):1057&#x2013;1060. doi: 10.1016/S2213-2600(20)30361-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30361-1</ArticleId><ArticleId IdType="pmc">PMC7447215</ArticleId><ArticleId IdType="pubmed">32857987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharat A, Machuca TN, Querrey M, Kurihara C, Garza-Castillon R, Jr., Kim S, et al. Early outcomes after lung transplantation for severe COVID-19: a&#xa0;series of the first consecutive cases from four countries. Lancet Respir Med. 2021;9(5):487&#x2013;497. doi: 10.1016/S2213-2600(21)00077-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00077-1</ArticleId><ArticleId IdType="pmc">PMC8012035</ArticleId><ArticleId IdType="pubmed">33811829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweiger T, Commentary HK. Post-COVID-19 acute respiratory distress syndrome and post-COVID-19 fibrosis-the new kids in town. J Thorac Cardiovasc Surg. 2022;163(3):869&#x2013;870. doi: 10.1016/j.jtcvs.2021.06.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2021.06.040</ArticleId><ArticleId IdType="pmc">PMC8230835</ArticleId><ArticleId IdType="pubmed">34274144</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck RW, Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239&#x2013;250. doi: 10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384(24):2273&#x2013;2282. doi: 10.1056/NEJMoa2104983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104983</ArticleId><ArticleId IdType="pmc">PMC8117969</ArticleId><ArticleId IdType="pubmed">33882218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384(23):2212&#x2013;2218. doi: 10.1056/NEJMoa2105000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105000</ArticleId><ArticleId IdType="pmc">PMC8117968</ArticleId><ArticleId IdType="pubmed">33882219</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092&#x2013;2101. doi: 10.1056/NEJMoa2104840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele T, Ulm L, Holtfreter S, Schonborn L, Kuhn SO, Scheer C, et al. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood. 2021;138(4):299&#x2013;303. doi: 10.1182/blood.2021012217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012217</ArticleId><ArticleId IdType="pmc">PMC8129797</ArticleId><ArticleId IdType="pubmed">33988688</ArticleId></ArticleIdList></Reference><Reference><Citation>Muster V, Gary T, Raggam RB, Wolfler A, Brodmann M. Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination. Lancet. 2021;397(10287):1842. doi: 10.1016/S0140-6736(21)00871-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00871-0</ArticleId><ArticleId IdType="pubmed">33864749</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Selleng K, Mayerle J, Palankar R, Wesche J, Reiche S, et al. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood. 2021;138(14):1269&#x2013;1277. doi: 10.1182/blood.2021012938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012938</ArticleId><ArticleId IdType="pmc">PMC8294553</ArticleId><ArticleId IdType="pubmed">34280256</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie. 2021;41(3):184&#x2013;189. doi: 10.1055/a-1469-7481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1469-7481</ArticleId><ArticleId IdType="pubmed">33822348</ArticleId></ArticleIdList></Reference><Reference><Citation>Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021;175(2):143&#x2013;156. doi: 10.1001/jamapediatrics.2020.4573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2020.4573</ArticleId><ArticleId IdType="pmc">PMC7519436</ArticleId><ArticleId IdType="pubmed">32975552</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monne M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a&#xa0;cohort study. Lancet Infect Dis. 2021;21(5):629&#x2013;636. doi: 10.1016/S1473-3099(20)30985-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30985-3</ArticleId><ArticleId IdType="pmc">PMC7906723</ArticleId><ArticleId IdType="pubmed">33545090</ArticleId></ArticleIdList></Reference><Reference><Citation>Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household transmission of SARS-coV-2: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(12):e2031756. doi: 10.1001/jamanetworkopen.2020.31756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.31756</ArticleId><ArticleId IdType="pmc">PMC7737089</ArticleId><ArticleId IdType="pubmed">33315116</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah K, Kandre Y, Mavalankar D. Secondary attack rate in household contacts of COVID-19 paediatric index cases: a&#xa0;study from Western India. J Public Health. 2021;43(2):243&#x2013;245. doi: 10.1093/pubmed/fdaa269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdaa269</ArticleId><ArticleId IdType="pmc">PMC7928715</ArticleId><ArticleId IdType="pubmed">33454742</ArticleId></ArticleIdList></Reference><Reference><Citation>Selva KJ, van de Sandt CE, Lemke MM, Lee CY, Shoffner SK, Chua BY, et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021;12(1):2037. doi: 10.1038/s41467-021-22236-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22236-7</ArticleId><ArticleId IdType="pmc">PMC8016934</ArticleId><ArticleId IdType="pubmed">33795692</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams PCM, Howard-Jones AR, Hsu P, Palasanthiran P, Gray PE, McMullan BJ, et al. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology. 2020;52(7):801&#x2013;808. doi: 10.1016/j.pathol.2020.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pathol.2020.08.001</ArticleId><ArticleId IdType="pmc">PMC7437539</ArticleId><ArticleId IdType="pubmed">32888706</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeb RT, Price S, Sliwa S, Kimball A, Szucs L, Caruso E, et al. COVID-19 trends among school-aged children&#x2014;United States, March 1&#x2013;September 19, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(39):1410&#x2013;1415. doi: 10.15585/mmwr.mm6939e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6939e2</ArticleId><ArticleId IdType="pmc">PMC7537558</ArticleId><ArticleId IdType="pubmed">33001869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzinger F, Santiago-Garcia B, Noguera-Julian A, Lanaspa M, Lancella L, Calo Carducci FI, et al. COVID-19 in children and adolescents in Europe: a&#xa0;multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653&#x2013;661. doi: 10.1016/S2352-4642(20)30177-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30177-2</ArticleId><ArticleId IdType="pmc">PMC7316447</ArticleId><ArticleId IdType="pubmed">32593339</ArticleId></ArticleIdList></Reference><Reference><Citation>Garazzino S, Vecchio LA, Pierantoni L, Calo Carducci FI, Marchetti F, Meini A, et al. Epidemiology, clinical features and prognostic factors of pediatric SARS-CoV-2 infection: results from an Italian multicenter study. Front Pediatr. 2021;9:649358. doi: 10.3389/fped.2021.649358.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2021.649358</ArticleId><ArticleId IdType="pmc">PMC8007917</ArticleId><ArticleId IdType="pubmed">33796491</ArticleId></ArticleIdList></Reference><Reference><Citation>Moeller&#xa0;A, Thanikkel&#xa0;L, Duijts&#xa0;L, Gaillard&#xa0;EA, Garcia-Marcos&#xa0;L, Kantar&#xa0;A, et&#xa0;al. COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres. ERJ Open Res. 2020;6(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682706</ArticleId><ArticleId IdType="pubmed">33263054</ArticleId></ArticleIdList></Reference><Reference><Citation>ECFS. COVID-CF project in Europe. 2021. https://www.ecfs.eu/covid-cf-project-europe. Accessed 10&#xa0;Jan 2022.</Citation></Reference><Reference><Citation>Zurl C, Eber E, Siegl A, Loeffler S, Stelzl E, Kessler HH, et al. Low rate of SARS-CoV-2 infections in symptomatic patients attending a&#xa0;pediatric emergency department. Front Pediatr. 2021;9:637167. doi: 10.3389/fped.2021.637167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2021.637167</ArticleId><ArticleId IdType="pmc">PMC8064389</ArticleId><ArticleId IdType="pubmed">33898359</ArticleId></ArticleIdList></Reference><Reference><Citation>Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607&#x2013;1608. doi: 10.1016/S0140-6736(20)31094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31094-1</ArticleId><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a&#xa0;systematic review. Eur J Pediatr. 2021;180(7):2019&#x2013;2034. doi: 10.1007/s00431-021-03993-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-03993-5</ArticleId><ArticleId IdType="pmc">PMC7890544</ArticleId><ArticleId IdType="pubmed">33599835</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021;385(1):11&#x2013;22. doi: 10.1056/NEJMoa2102968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102968</ArticleId><ArticleId IdType="pmc">PMC8220965</ArticleId><ArticleId IdType="pubmed">34133854</ArticleId></ArticleIdList></Reference><Reference><Citation>Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. Multisystem inflammatory syndrome in children&#x2014;initial therapy and outcomes. N Engl J Med. 2021;385(1):23&#x2013;34. doi: 10.1056/NEJMoa2102605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102605</ArticleId><ArticleId IdType="pmc">PMC8220972</ArticleId><ArticleId IdType="pubmed">34133855</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsenstein S, Duong P, Lane S, Jones C, Pain CE, Hedrich CM. Cardiac pathology and outcomes vary between Kawasaki disease and PIMS-TS. Clin Immunol. 2021;229:108780. doi: 10.1016/j.clim.2021.108780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108780</ArticleId><ArticleId IdType="pubmed">34118400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahrami H, BaHammam AS, Bragazzi NL, Saif Z, Faris M, Vitiello MV. Sleep problems during the COVID-19 pandemic by population: a&#xa0;systematic review and meta-analysis. J Clin Sleep Med. 2021;17(2):299&#x2013;313. doi: 10.5664/jcsm.8930.</Citation><ArticleIdList><ArticleId IdType="doi">10.5664/jcsm.8930</ArticleId><ArticleId IdType="pmc">PMC7853219</ArticleId><ArticleId IdType="pubmed">33108269</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a&#xa0;prospective UK cohort. Thorax. 2021;76(4):399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas MB, Kim M, Malkani RG, Abbott SM, Zee PC. Obstructive sleep apnea and risk of COVID-19 infection, hospitalization and respiratory failure. Sleep Breath. 2021;25(2):1155&#x2013;1157. doi: 10.1007/s11325-020-02203-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11325-020-02203-0</ArticleId><ArticleId IdType="pmc">PMC7521948</ArticleId><ArticleId IdType="pubmed">32989673</ArticleId></ArticleIdList></Reference><Reference><Citation>Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500&#x2013;1515. doi: 10.1007/s00125-020-05180-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-020-05180-x</ArticleId><ArticleId IdType="pmc">PMC7256180</ArticleId><ArticleId IdType="pubmed">32472191</ArticleId></ArticleIdList></Reference><Reference><Citation>Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612&#x2013;1614. doi: 10.1001/jama.2020.4326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4326</ArticleId><ArticleId IdType="pmc">PMC7082763</ArticleId><ArticleId IdType="pubmed">32191259</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region&#x2014;case series. N Engl J Med. 2020;382(21):2012&#x2013;2022. doi: 10.1056/NEJMoa2004500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2004500</ArticleId><ArticleId IdType="pmc">PMC7143164</ArticleId><ArticleId IdType="pubmed">32227758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lance CG. PAP therapy increases the risk of transmission of COVID-19. Cleve Clin J Med. 2020 doi: 10.3949/ccjm.87a.ccc003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.87a.ccc003</ArticleId><ArticleId IdType="pubmed">32371560</ArticleId></ArticleIdList></Reference><Reference><Citation>Attias D, Pepin JL, Pathak A. Impact of COVID-19 lockdown on adherence to continuous positive airway pressure by obstructive sleep apnoea patients. Eur Respir&#xa0;J. 2020 doi: 10.1183/13993003.01607-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01607-2020</ArticleId><ArticleId IdType="pmc">PMC7241111</ArticleId><ArticleId IdType="pubmed">32430426</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430&#x2013;436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Asthma and COVID-19: scientific brief. 2021. https://www.who.int/publications/i/item/who-2019-ncov-sci-brief-asthma-2021.1. Accessed 10&#xa0;Jan 2022.</Citation></Reference><Reference><Citation>Caminati M, Vultaggio A, Matucci A, Senna G, Almerigogna F, Bagnasco D, et al. Asthma in a&#xa0;large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;176:106261. doi: 10.1016/j.rmed.2020.106261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106261</ArticleId><ArticleId IdType="pmc">PMC7688414</ArticleId><ArticleId IdType="pubmed">33260107</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83&#x2013;90. doi: 10.1164/rccm.202003-0821OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0821OC</ArticleId><ArticleId IdType="pmc">PMC7328313</ArticleId><ArticleId IdType="pubmed">32348692</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan S, Nicolau DV, Jr., Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a&#xa0;phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763&#x2013;772. doi: 10.1016/S2213-2600(21)00160-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00160-0</ArticleId><ArticleId IdType="pmc">PMC8040526</ArticleId><ArticleId IdType="pubmed">33844996</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu LM, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a&#xa0;randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843&#x2013;855. doi: 10.1016/S0140-6736(21)01744-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01744-X</ArticleId><ArticleId IdType="pmc">PMC8354567</ArticleId><ArticleId IdType="pubmed">34388395</ArticleId></ArticleIdList></Reference><Reference><Citation>Adir Y, Humbert M, Saliba W. COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence. J Allergy Clin Immunol. 2021;148(2):361&#x2013;367. doi: 10.1016/j.jaci.2021.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.06.006</ArticleId><ArticleId IdType="pmc">PMC8205279</ArticleId><ArticleId IdType="pubmed">34144110</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang QM, Zhang PD, Li ZH, Zhou JM, Liu D, Zhang XR, et al. Genetic Risk and Chronic Obstructive Pulmonary Disease Independently Predict the Risk of Incident Severe COVID-19. Ann Am Thorac Soc. 2022;19(1):58&#x2013;65. doi: 10.1513/AnnalsATS.202102-171OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202102-171OC</ArticleId><ArticleId IdType="pmc">PMC8787794</ArticleId><ArticleId IdType="pubmed">34242153</ArticleId></ArticleIdList></Reference><Reference><Citation>Flie&#xdf;er E, Birnhuber A, Marsh LM, Gschwandtner E, Klepetko W, Olschewski H, et al. Dysbalance of ACE2 levels&#x2014;a&#xa0;possible cause for severe COVID-19 outcome in COPD. J Pathol Clin Res. 2021;7(5):446&#x2013;458. doi: 10.1002/cjp2.224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cjp2.224</ArticleId><ArticleId IdType="pmc">PMC8239572</ArticleId><ArticleId IdType="pubmed">33978304</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson A, Oberg L, Angermann B, Spalluto CM, Huhn M, Burke H, et al. Dysregulation of COVID-19 related gene expression in the COPD lung. Respir Res. 2021;22(1):164. doi: 10.1186/s12931-021-01755-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01755-3</ArticleId><ArticleId IdType="pmc">PMC8164067</ArticleId><ArticleId IdType="pubmed">34051791</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen P, Majumdar U, Zein J, Hatipoglu U, Attaway AH. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: an analysis of Cleveland Clinic&#x2019;s COVID-19 registry. PLoS ONE. 2021;16(6):e0252576. doi: 10.1371/journal.pone.0252576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0252576</ArticleId><ArticleId IdType="pmc">PMC8174679</ArticleId><ArticleId IdType="pubmed">34081722</ArticleId></ArticleIdList></Reference><Reference><Citation>So JY, O&#x2019;Hara NN, Kenaa B, Williams JG, deBorja CL, Slejko JF, et al. Decline in COPD admissions during the COVID-19 pandemic associated with lower burden of community respiratory viral infections. Am J Med. 2021;134(10):1252&#x2013;1259. doi: 10.1016/j.amjmed.2021.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2021.05.008</ArticleId><ArticleId IdType="pmc">PMC8196237</ArticleId><ArticleId IdType="pubmed">34126098</ArticleId></ArticleIdList></Reference><Reference><Citation>Revon-Riviere G, Soler C, Andrianarivony T, Fily S, Andre N. Favorable outcome of COVID-19 infection in a&#xa0;pediatric cancer patient receiving an anti-PD-L1/anti-CTLA-4 combination. J Pediatr Hematol Oncol. 2021;43(7):e1045&#x2013;e6. doi: 10.1097/MPH.0000000000002099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPH.0000000000002099</ArticleId><ArticleId IdType="pubmed">33625085</ArticleId></ArticleIdList></Reference><Reference><Citation>Dipasquale A, Persico P, Lorenzi E, Rahal D, Santoro A, Simonelli M. COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report. J Immunother Cancer. 2021 doi: 10.1136/jitc-2020-001870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001870</ArticleId><ArticleId IdType="pmc">PMC7880093</ArticleId><ArticleId IdType="pubmed">33574054</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299(1):E177&#x2013;E186. doi: 10.1148/radiol.2021203153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021203153</ArticleId><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. Persistent post-COVID-19 inflammatory interstitial lung disease: an observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18(5):799&#x2013;806. doi: 10.1513/AnnalsATS.202008-1002OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202008-1002OC</ArticleId><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito AJ, Menon AA, Ghosh AJ, Putman RK, Fredenburgh LE, El-Chemaly SY, et al. Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study. Am J Respir Crit Care Med. 2020;202(12):1710&#x2013;1713. doi: 10.1164/rccm.202006-2441LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202006-2441LE</ArticleId><ArticleId IdType="pmc">PMC7737588</ArticleId><ArticleId IdType="pubmed">32897754</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med. 2020;202(12):1656&#x2013;1665. doi: 10.1164/rccm.202007-2794OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202007-2794OC</ArticleId><ArticleId IdType="pmc">PMC7737581</ArticleId><ArticleId IdType="pubmed">33007173</ArticleId></ArticleIdList></Reference><Reference><Citation>Godinas L, Iyer K, Meszaros G, Quarck R, Escribano-Subias P, Vonk Noordegraaf A, et al. PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. Orphanet J Rare Dis. 2021;16(1):196. doi: 10.1186/s13023-021-01752-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-021-01752-1</ArticleId><ArticleId IdType="pmc">PMC8087873</ArticleId><ArticleId IdType="pubmed">33933110</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D, Certain M, Savale L, Ja&#xef;s X, Humbert M, Sitbon O, The French P.H Network Pulmotension Investigators . Late Breaking Abstract&#x2014;COVID-19 in patients with pulmonary hypertension: a&#xa0;national prospective cohort study. France: Pulmotension; 2021.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence; 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Boon G, Barco S, Endres M, Geelhoed JJM, Knauss S, et al. The Post-COVID-19 Functional Status scale: a&#xa0;tool to measure functional status over time after COVID-19. Eur Respir&#xa0;J. 2020 doi: 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gloeckl R, Leitl D, Jarosch I, Schneeberger T, Nell C, Stenzel N, et al. Benefits of pulmonary rehabilitation in COVID-19: a&#xa0;prospective observational cohort study. ERJ Open Res. 2021 doi: 10.1183/23120541.00108-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00108-2021</ArticleId><ArticleId IdType="pmc">PMC7957293</ArticleId><ArticleId IdType="pubmed">34095290</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielmanns M, Pekacka-Egli AM, Schoendorf S, Windisch W, Hermann M. Effects of a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients. Int J Environ Res Public Health. 2021 doi: 10.3390/ijerph18052695.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052695</ArticleId><ArticleId IdType="pmc">PMC7967422</ArticleId><ArticleId IdType="pubmed">33800094</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Chikhanie Y, Veale D, Schoeffler M, Pepin JL, Verges S, Herengt F. Effectiveness of pulmonary rehabilitation in COVID-19 respiratory failure patients post-ICU. Respir Physiol Neurobiol. 2021;287:103639. doi: 10.1016/j.resp.2021.103639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2021.103639</ArticleId><ArticleId IdType="pmc">PMC7879818</ArticleId><ArticleId IdType="pubmed">33588090</ArticleId></ArticleIdList></Reference><Reference><Citation>AWMF. S3-Leitlinie zur kardiologischen Rehabilitation (LL-KardReha) im deutschsprachigen Raum Europas, Deutschland, &#xd6;sterreich, Schweiz (D-A-CH), Langversion. 2020. https://www.awmf.org/leitlinien/detail/ll/133-001.html. Accessed 10&#xa0;Jan 2022.</Citation></Reference><Reference><Citation>Schlitt ASK, Platz T. AWMF-Leitlinie: Rehabilitation nach einer COVID-19-Erkrankung. Dtsch Arztebl. 2021;:A-774/B-648. https://www.aerzteblatt.de/archiv/inhalt?heftid=6578. Accessed 10&#xa0;Jan 2022.</Citation></Reference><Reference><Citation>Ethikrat. Ethikrat legt Empfehlungen zur Bew&#xe4;ltigung der Pandemie vor. 2020. https://www.aerzteblatt.de/nachrichten/111469/ethikrat-legt-Empfehlungen-zur-Bewaeltigung-der-Pandemie-vor. Accessed 10&#xa0;Jan 2022.</Citation></Reference><Reference><Citation>BAGSO. Zur verfassungsrechtlichen Beurteilung von Besuchs- und Ausgangsbeschr&#xe4;nkungen in Alten- und Pflegeheimen aus Anlass der COVID-19-Pandemie. https://www.bagso.de/publikationen/stellungnahme/rechtsgutachten-besuche-in-pflegheimen/. Accessed 10&#xa0;Jan 2022.</Citation></Reference><Reference><Citation>DHOE. M&#xf6;glichkeiten der Lebens&#x2011;, Sterbe- und Trauerbegleitung ohne physischen Kontakt. 2020. https://www.hospiz.at/moeglichkeiten-in-der-lebens-sterbe-und-trauerbegleitung-ohne-physischen-kontakt/. Accessed 10&#xa0;Jan 2022.</Citation></Reference><Reference><Citation>Gosch M, Heppner HJ, Lim S, Singler K. Recommendations for the management of COVID-19 pandemic in long-term care facilities. Z Gerontol Geriatr. 2021;54(2):136&#x2013;140. doi: 10.1007/s00391-021-01847-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00391-021-01847-1</ArticleId><ArticleId IdType="pmc">PMC7810427</ArticleId><ArticleId IdType="pubmed">33452539</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch U, Muller H, Deffner T, von Schmude A, Kern M, Kiepke-Ziemes S, et al. Recommendations for the support of suffering, severely ill, dying or grieving persons in the corona pandemic from a&#xa0;palliative care perspective: Recommendations of the German Society for Palliative Medicine (DGP), the German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI), the Federal Association for Grief Counseling (BVT), the Working Group for Psycho-oncology in the German Cancer Society, the German Association for Social Work in the Healthcare System (DVSG) and the German Association for Systemic Therapy, Counseling and Family Therapy (DGSF) Schmerz. 2020;34(4):303&#x2013;313. doi: 10.1007/s00482-020-00483-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00482-020-00483-9</ArticleId><ArticleId IdType="pmc">PMC7265165</ArticleId><ArticleId IdType="pubmed">32488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas P, Baldwin C, Bissett B, Boden I, Gosselink R, Granger CL, et al. Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations. J Physiother. 2020;66(2):73&#x2013;82. doi: 10.1016/j.jphys.2020.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphys.2020.03.011</ArticleId><ArticleId IdType="pmc">PMC7165238</ArticleId><ArticleId IdType="pubmed">32312646</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglini D, Robba C, Caiffa S, Ball L, Brunetti I, Loconte M, et al. Chest physiotherapy: an important adjuvant in critically ill mechanically ventilated patients with COVID-19. Respir Physiol Neurobiol. 2020;282:103529. doi: 10.1016/j.resp.2020.103529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2020.103529</ArticleId><ArticleId IdType="pmc">PMC7430249</ArticleId><ArticleId IdType="pubmed">32818606</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten-Barentsz KM, van Oorsouw R, Klooster E, Koenders N, Driehuis F, Hulzebos EHJ, et al. Recommendations for hospital-based physical therapists managing patients with COVID-19. Phys Ther. 2020;100(9):1444&#x2013;1457. doi: 10.1093/ptj/pzaa114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ptj/pzaa114</ArticleId><ArticleId IdType="pmc">PMC7337861</ArticleId><ArticleId IdType="pubmed">32556323</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggmann S, Kindler A, Perren A, Ott N, Johannes F, Vollenweider R, et al. Early physical therapist interventions for patients with COVID-19 in the acute care hospital: a case report series. Phys Ther. 2021 doi: 10.1093/ptj/pzaa194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ptj/pzaa194</ArticleId><ArticleId IdType="pmc">PMC7665777</ArticleId><ArticleId IdType="pubmed">33492400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>